Increasing African Immigrant Women's Participation in Breast Cancer Screening
New York City (NYC) is home to a large and diverse immigrant population. Many of these groups
face significant barriers to preventive health care, including lack of insurance, poor health
care access and language difficulties. Most African immigrant women are likely t...
Age: 18 - 74 years
Gender: All
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
The purpose of this study is to find out the possible anti-cancer effect of pelareorep in
combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer
called Hormone Receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2
ne...
Age: 18 years - 66+
Gender: Female
Vaccination With Flt3L, Radiation, and Poly-ICLC
This is a combination of 4 therapies, three of which are used to treat a single "target site"
of your cancer (such as a lymph node or a single tumor), and the 4th is given directly into
the blood stream (intravenous or "IV").
1. Radiation: The target site --lymph nod...
Age: 18 years - 66+
Gender: All
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Triple negative breast cancer (TNBC) represents about 15% of breast cancers and is
characterized by the lack of expression of estrogen receptor (ER), progesterone receptor
(PR), and HER-2 non-amplification. Women with TNBC tend to be younger, African American, and
BR...
Age: 18 years - 66+
Gender: Female
Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual
care that includes regional radiation therapy, with receiving no regional radiation therapy.
Researchers want to see if not giving this type of radiation treatment works as...
Age: 40 years - 66+
Gender: Female
A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
Patients will receive intra-tumoral (IT) NKTR-262 in 3-week treatment cycles. During the
Phase 1 dose escalation portion of the trial, NKTR-262 will be combined with systemic
administration of bempegaldesleukin. After determination of the recommended Phase 2 dose
(RP...
Age: 18 years - 66+
Gender: All
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Primary Objective:
• Determination of pathologic complete response (pCR) rates
Secondary Objective:
- Determination of cardiac toxicity as measured by: composite of LVEF, longitudinal strain
and troponin.
- Breast conservation rates
- Overall survival
Study Desig...
Age: 18 years - 66+
Gender: Female
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast
This is a multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and
pertuzumab is proposed as first-line therapy in metastatic hormone receptor-positive,
HER2-positive breast cancer patients. In this phase I/II clinical trial, the researchers aim
to...
Age: 18 years - 66+
Gender: Female
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with
or without atezolizumab works in treating patients with breast cancer that has spread to
other parts of the body (metastatic). Drugs used in chemotherapy, such as paclitaxel,...
Age: 18 years - 66+
Gender: All
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
This randomized phase III trial studies how well pembrolizumab works in treating patients
with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with...
Age: 18 years - 66+
Gender: All
Breast Cancer WEight Loss Study (BWEL Study)
This randomized phase III trial studies whether weight loss in overweight and obese women may
prevent breast cancer from coming back (recurrence). Previous studies have found that women
who are overweight or obese when their breast cancer is found (diagnosed) have a...
Age: 18 years - 66+
Gender: Female
Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
The purpose of this study is to evaluate the safety and effectiveness of carboplatin compared
to the combination of carboplatin and everolimus for the treatment of advanced
triple-negative breast cancer (TNBC).
Age: 18 years - 66+
Gender: Female
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
This randomized phase III trial studies how well doxorubicin hydrochloride and
cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients
with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin
hydrochlor...
Age: 18 years - 66+
Gender: All
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Ge...
Age: 18 years - 66+
Gender: All
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
This phase II trial studies F-18 16 alpha-fluoroestradiol (FES) positron emission tomography
(PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with
newly diagnosed breast cancer that has spread to other parts of the body. FES is ...
Age: 18 years - 66+
Gender: All
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
This randomized phase III trial studies metformin hydrochloride to see how well it works
compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in
situ breast cancer. Chemoprevention is the use of certain drugs to keep cancer from for...
Age: 25 - 55 years
Gender: Female
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
This randomized phase III trial studies lymph node dissection and radiation therapy to see
how well it works compared to radiation therapy alone in treating patients with breast cancer
previously treated with chemotherapy and surgery. Lymph node dissection may remove ...
Age: 18 years - 66+
Gender: All
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
This randomized phase III trial studies lymph node dissection and radiation therapy to see
how well it works compared to radiation therapy alone in treating patients with breast cancer
previously treated with chemotherapy and surgery. Lymph node dissection may remov...
Age: 18 years - 66+
Gender: All
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
The study will be a multi-center, prospective, randomized, single-blinded, placebo-controlled
Phase II trial of Herceptin + NeuVax(TM) vaccine (E75 peptide/granulocyte macrophage-colony
stimulating factor) (GM-CSF) versus Herceptin + GM-CSF alone. The target study pop...
Age: 18 years - 66+
Gender: Female